Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more
Antibody-drug conjugates (ADCs) have become an important treatment method in the field of oncology, offering superior clinical characteristics compared to chemotherapy. However, the application of ADCs still faces two significant challenges. First, there are very few validated payloads with proven mechanisms of action (MoA), which limits the expansion of indications. Approved ADC payloads cover three … Read more
Since 2000, the ADC field has gradually started to be pushed to market, and in recent years, it has emerged rapidly in the field of cancer treatment, leading to intense competition. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology areas. Although the number of related ADCs is extremely limited and most … Read more
Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin, trade name: Mylotarg) was approved for the treatment of CD33-positive acute myeloid … Read more
Introduction Antibody-drug conjugates(ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. ADC consists of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug … Read more
What Is ADC? Antibody-drug conjugates (ADC) are a new type of targeted therapeutic drug, composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers. They combine the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. This structure allowsADC to deliver drugs directly … Read more
Nanobodies（Nanobody, Nbs） are a new member of the antibody family, characterized by their relatively small molecular weight, ease of humanization, high affinity, high stability, microbial expression capability, low immunogenicity, strong penetration ability, and good solubility. They have attracted significant attention in basic medical research as well as disease diagnosis and treatment. Introduction to Nanobodies 1. … Read more
The 4th Global Biopharmaceutical Frontier Technology Conference and Exhibition is Open for Registration! The story of the “magic bullet” ADC has clearly not reached its final chapter. With the advent of DS-8201, the global ADC market has become exceptionally vibrant, entering a period of rapid growth. The market’s enthusiasm for ADCs is evident from the … Read more